Leading Institutions
32 of 32
Searching for:
Id |
Institute Name |
Research Focus |
Key Achievements |
Platforms Used |
Website |
|---|---|---|---|---|---|
| 9 | Chula Vaccine Research Center Thailand | Academic vaccine center (Chulalongkorn Univ.); mRNA vaccines for COVID-19, dengue, HIV, etc. | Developed ChulaCov19, Thailand’s first mRNA COVID-19 vaccine (showed high immunogenicity in Phase I/II); created a bivalent Omicron-adapted mRNA booster (Comvigen) – in a Phase II trial it proved non-inferior to Pfizer’s booster; established international collaborations (UPenn, Genevant) for LNP and mRNA tech transfer | N1-methyl-pseudouridine modified mRNA (LNP-based) platform (developed with UPenn/Genevant); also exploring self-amplifying mRNA for dengue and other diseases in preclinical stages | https://www.chulavrc.org/ |
| 10 | Gennova Biopharmaceuticals India | Biotechnology company; developing next-gen mRNA vaccines for COVID-19 variants and viral diseases | Created India’s first indigenous mRNA vaccine (GEMCOVAC-19) for COVID-19 – one of the first three mRNA COVID vaccines worldwide; developed a variant-specific booster (GEMCOVAC-OM) with improved thermostability; now working on an mRNA Nipah virus vaccine with CEPI support | Self-amplifying mRNA (saRNA) platform (lyophilized LNP formulation, 2–8°C storage); also uses nucleoside-modified mRNA for multivalent vaccines | https://gennova.bio/ |
| 31 | Walvax Biotechnology Co China | Biotechnology company; mRNA vaccine development for COVID-19 and other diseases (with partners) | Co-developed ARCoV/AWcorna, China’s first home-grown mRNA COVID-19 vaccine (with Suzhou Abogen & Academy of Military Medical Sciences) – showed ~84% efficacy against original strain; EUA granted in Indonesia (2022) and trials conducted internationally | Nucleoside-modified mRNA (encoding viral RBD) in LNP – notably thermostable (stable ~1 week at room temp); also exploring new lipid formulations | https://walvax.com/ |
| 11 | German Cancer Research Center (DKFZ) – Helmholtz Institute Mainz Geramy | Cancer immunotherapy, mRNA vaccines | Home to the Helmholtz Institute for mRNA-based Cancer Immunotherapies, in partnership with BioNTech. DKFZ-affiliated scientists U?ur ?ahin and Özlem Türeci (who co-founded BioNTech) helped design the COVID-19 mRNA vaccine and are now leading mRNA cancer vaccine trials. Key achievements include pioneering personalized mRNA cancer vaccines (e.g. for melanoma) and contributing to the rapid development of COVID-19 vaccines. | mRNA vaccines for cancer & infectious disease (LNP-based personalized vaccines) | dkfz.de |
| 21 | Max Planck Institute (e.g. MPI of Molecular Physiology, Dortmund) Germany | Fundamental RNA biology, delivery chemistry | Max Planck researchers made key contributions to enabling mRNA therapeutics. In 2024, an MPI team developed the first small-molecule inhibitor of mRNA deadenylation, which prevents mRNA degradation. This breakthrough opens new avenues to enhance mRNA stability for vaccines and treatments. Other Max Planck groups have advanced polymer-based mRNA delivery and basic RNA biology, underpinning vaccine innovations. | Platform-agnostic (basic research supporting all mRNA platforms) | https://www.mpg.de/de |
| 19 | International Vaccine Institute (IVI) South Korea (International) | Global vaccine development, epidemic preparedness | An international non-profit institute, IVI is advancing mRNA vaccine technology for global health. In 2024, an IVI-led consortium won funding to build an ultra-rapid mRNA vaccine production system – aiming to produce 1 million doses within 100 days of a new pandemic. This project will modularize the entire mRNA manufacturing process (from design to LNP formulation) to enable swift responses to outbreaks. IVI also collaborates on mRNA vaccine R&D for diseases affecting low-income countries, leveraging its expertise in clinical evaluation and capacity building. | mRNA vaccine platforms (modular manufacturing, LNP delivery) | https://www.ivi.int/ |
| 22 | National Institute of Health (NIH) (Pakistan) Pakistan | Government public health institute; establishing mRNA vaccine R&D and manufacturing capability | Selected as Pakistan’s mRNA vaccine hub recipient; researchers trained via WHO hub to kick-start Pakistan’s first mRNA vaccine production (aiming at COVID-19 and other vaccines for national programs) | ModifiedmRNA–LNP platform (WHO hub technology); focus on developing in-country production for pandemic response | https://www.nih.org.pk/ |
| 23 | National Institutes of Health (Vaccine Research Center) United States | Infectious disease vaccines, immunology | Co-developed the prefusion-stabilized spike protein antigen used in leading COVID-19 mRNA vaccines; collaborated with Moderna to create the mRNA-1273 vaccine, which proved safe and highly effective. Also working on pan-coronavirus and universal influenza mRNA vaccines. | LNP-formulated mRNA vaccines | https://www.nih.gov/ |
| 15 | Institut Pasteur France | Infectious diseases, global health vaccines | Renowned for vaccine innovation historically, Pasteur Institute is now investing in mRNA technology. It established an ambitious mRNA vaccine R&D program as part of its Pasteur 2030 plan, including strategic alliances with Fiocruz (Brazil) and Sanofi to develop new mRNA vaccines. Pasteur’s efforts aim to accelerate vaccine development for emergent pathogens using mRNA platforms, building on its network of international research centers. | mRNA vaccine platforms (LNP-based) for infectious diseases | https://www.pasteur.fr/fr |
| 29 | University of Pennsylvania (Penn) United States | Infectious diseases, immunotherapy, RNA biology | Pioneered nucleoside-modified mRNA for vaccines; Penn’s discoveries by Karikó & Weissman enabled the first COVID-19 mRNA vaccines (Nobel Prize in 2023). Now developing mRNA vaccines for influenza, HIV, herpes, pan-coronaviruses, etc. | Modified mRNA in lipid nanoparticles (LNP) | https://www.upenn.edu/ |
| 13 | Imperial College London United Kingdom | Infectious diseases, self-amplifying RNA vaccines | Developed a self-amplifying RNA (saRNA) COVID-19 vaccine platform. Imperial’s saRNA vaccine was among the first COVID-19 candidates to enter clinical trials, showing no serious safety concerns and inducing immune responses in up to 87% of participants even at ultra-low doses. The program (led by Robin Shattock) is refining saRNA for higher consistency and expanding it to other diseases (e.g. rabies, Ebola). | Self-amplifying mRNA vaccines delivered via LNPs | https://www.imperial.ac.uk/ |
| 14 | Incepta Vaccine Ltd. Bangladesh | Leading vaccine manufacturer; adopting mRNA technology for future pandemics and local needs | Only Bangladeshi member of WHO global mRNA hub, enabling rapid development of mRNA vaccines for new outbreaks; built broad vaccine portfolio (16 human vaccines) to improve self-sufficiency | ModRNA–LNP platform (via WHO hub); emphasizing quick-turnaround production for emerging diseases | https://inceptavaccine.com/ |
| 28 | University of British Columbia (UBC) Canada | Lipid nanoparticles, RNA drug delivery | UBC researchers (e.g. Pieter Cullis) invented the ionizable lipid nanoparticle technology that protects mRNA and enables its delivery into cells. This LNP platform was an “unsung hero” of COVID-19 mRNA vaccines, turning a once-fringe field into a mainstream success. UBC’s advances in LNP formulation and manufacturing (microfluidics, novel lipids) underpin Pfizer-BioNTech’s vaccine and other mRNA therapies. | Lipid nanoparticle (LNP) delivery systems for mRNA | https://www.ubc.ca/ |
| 30 | University of Queensland (UQ – BASE Facility) | mRNA vaccine production, clinical translation | UQ has become a leader in mRNA R&D and manufacturing in Australia. Its BASE facility (launched 2021) is the country’s top provider of research-grade mRNA and is now expanding to a GMP-ready mRNA production lab for clinical trials. Backed by government and industry (e.g. Sanofi), UQ will have end-to-end capability – from mRNA design to pilot-scale manufacturing – enabling Phase I trials of next-gen mRNA vaccines in 2024. This boosts Australia’s pandemic preparedness and biotech ecosystem. | Standard mRNA vaccine platform (LNP-formulated), on-site manufacturing for trials | https://uq.edu.au/ |
| 2 | Afrigen Biologics & Vaccines South Africa | mRNA vaccine R&D for COVID-19 and emerging diseases (e.g. Rift Valley fever) | Developed Africa’s first indigenous mRNA COVID-19 vaccine (AfriVac 2021); advancing a first-ever mRNA vaccine for Rift Valley fever (in partnership with CEPI) | N1-methyl-pseudouridine modified mRNA (LNP formulation); exploring next-gen stable mRNA tech | https://www.afrigen.co.za/ |
| 20 | Massachusetts Institute of Technology (MIT) United States | Nanotechnology, drug delivery platforms | Pioneered lipid nanoparticle (LNP) carriers for mRNA delivery – a decades-long effort led by MIT scientists (Robert Langer, Daniel Anderson, etc.) that was crucial to the success of Moderna’s and Pfizer-BioNTech’s COVID-19 mRNA vaccines. Ongoing innovations include new ionizable lipids and polymers to improve mRNA vaccine efficacy and stability. | Lipid nanoparticles; novel polymer and lipid-based mRNA delivery systems | https://web.mit.edu/ |
| 18 | Institut Torlak Serbia | National vaccine institute; revitalizing vaccine production including mRNA technology | Designated as Eastern Europe’s WHO mRNA spoke to acquire mRNA vaccine know-how; planning to produce mRNA vaccines (building on a long history of vaccine production in the Balkans) | ModRNA–LNP platform (WHO hub technology); integrating mRNA into traditional vaccine R&D programs | https://torlak.rs/en/naslovna-english/ |
| 12 | Harvard University (Harvard Medical School) United States | Next-gen vaccine design, cancer immunotherapy | Developed novel mRNA vaccine strategies to improve immune responses – e.g. an mRNA-based IL-12 adjuvant technology that boosts potency and durability of vaccines while reducing side effects (in preclinical COVID-19 studies). Harvard-affiliated researchers are also exploring mRNA cancer vaccines and universal vaccines. | Standard mRNA vaccines in LNPs (with novel immunomodulators) | https://hms.harvard.edu/ |
| 5 | BioGeneric Pharma Eygept | Private biotech focused on vaccines; building mRNA vaccine manufacturing for Egypt & Africa | Chosen by WHO as mRNA tech transfer recipient (2022); partnering with Afrigen to develop new mRNA vaccines (targeting antimicrobial-resistant infections and respiratory diseases) | Modified mRNA–LNP platform (via WHO hub); expanding mRNA production capacity for regional needs | https://biogenericpharma.com/ |
| 4 | Bio-Manguinhos / Fiocruz Brazil | Public biotech institute for vaccines; establishing mRNA vaccine R&D and production in LatAm | Selected by WHO/PAHO as Latin America’s mRNA vaccine hub; installed an mRNA production platform (Quantoom Ntensify) in 2024; MoU to develop 2nd-gen self-amplifying RNA (saRNA) vaccines for infectious diseases | Self-amplifying mRNA (saRNA) and conventional mRNA–LNP platforms (via Quantoom technology); integrating local manufacturing capacity | fiocruz.br/bio-manguinhos |
| 24 | Oswaldo Cruz Foundation (Fiocruz) Brazil | Public health vaccines, local manufacturing | Brazil’s premier public health institute (through its Bio-Manguinhos unit) has built the country’s first mRNA vaccine platform. Fiocruz is advancing a homegrown mRNA COVID-19 vaccine (using an authorized sequence from Moderna) and completed preclinical studies by 2023. It is part of the WHO mRNA hub network and has a strategic alliance with Institut Pasteur and Sanofi to develop new mRNA vaccines. Fiocruz’s work is set to reduce Brazil’s reliance on imports by enabling domestic production of mRNA vaccines for COVID-19 and other diseases. | mRNA vaccines (LNP-based, tech-transfer through WHO/PAHO) | https://fiocruz.br/ |
| 16 | Institut Pasteur de Dakar (IPD Senegal | Public institute; expanding into mRNA vaccine production for Africa (COVID-19, endemic diseases) | Partnered with BioNTech to host a new mRNA vaccine manufacturing facility in Senegal (agreement signed 2021); part of Pasteur Network’s 2024 MoU to boost mRNA R&D and production in Africa | ModRNA–LNP platform (via BioNTech and WHO hub technology); focus on scalable manufacturing modules for Africa | https://institutpasteurdakar.sn/ |
| 17 | Institut Pasteur de Tunis Tunisia | Public research institute; pursuing mRNA vaccine R&D for regional health threats | Chosen as mRNA tech transfer partner (WHO hub) in MENA; in 2024 joined Pasteur Network initiative to expand mRNA vaccine research & production in low-resource regions | ModRNA–LNP platform (WHO hub technology); building local R&D and production capacity through international collaboration | https://pasteur.tn/ |
| 25 | Polyvac Vietnam | Public vaccine R&D institute; expanding capabilities to include mRNA vaccine development | Chosen as Vietnam’s mRNA hub recipient (as part of WHO program); gearing up to produce mRNA vaccines for domestic use (initially targeting COVID-19 and other infectious diseases in Vietnam) | ModRNA–LNP platform (WHO hub technology); developing local workforce & facilities for mRNA vaccine production | https://dcvmn.org/member/polyvac/ (Ministry of Health VN) |
| 7 | Biovac Institute South Africa | Public–private vaccine manufacturer; mRNA vaccine production (COVID-19 & future pandemics) | First recipient of WHO hub technology transfer – completed tech transfer training and scale-up in 2024; preparing to manufacture Afrigen’s mRNA COVID vaccine for Africa | ModRNA–LNP platform (technology transferred from Afrigen/WHO hub); focus on scalable GMP production | https://biovac.co.za/ |
| 8 | Biovaccines Nigeria Ltd. Nigeria | Public-private vaccine venture; aiming for local production of mRNA vaccines (COVID-19, others) | Selected as Nigeria’s recipient of WHO mRNA tech transfer in 2022 (JV of govt & May&Baker); team trained at Afrigen hub to establish Nigeria’s first mRNA vaccine facility | ModRNA–LNP platform (WHO hub technology); focusing on capacity building for domestic mRNA manufacturing | https://biovaccinesnig.com/ |
| 3 | Bio Farma Indonesia | State-owned vaccine producer; expanding production to include mRNA vaccines (COVID-19, etc.) | Selected for WHO mRNA hub; completed technology transfer training at Afrigen in 2022 (one of the first to do so); now implementing mRNA production for regional vaccine supply security | ModRNA–LNP platform (WHO hub technology); integrating mRNA into existing large-scale manufacturing pipeline | https://www.biofarma.co.id/ |
| 27 | Translational Health Science and Technology Institute (THSTI) India | Translational vaccine research, pandemic threats | A public research institute under India’s DBT, THSTI contributed to COVID-19 vaccine efforts and is now focusing on indigenous mRNA vaccines. It is developing a pan-beta-coronavirus mRNA vaccine in collaboration with industry (Panacea Biotec), funded by CEPI. THSTI has also partnered internationally (e.g. with IAVI and a Korean firm) on novel mRNA platforms with improved thermal stability. These initiatives aim to establish India’s own mRNA vaccine capacity and address regional diseases. | mRNA vaccine platform development (LNP-based, exploring thermostable mRNA) | https://thsti.res.in/ |
| 6 | Biological E. Ltd. India | Vaccine and biologics company; developing mRNA vaccines via global collaborations | Partnered with Canada’s Providence to license and produce an mRNA COVID-19 vaccine (PTX-COVID19-B) in India; chosen by WHO as India’s mRNA tech transfer recipient to build domestic mRNA capacity | Modified mRNA–LNP platform (in-licensed technology); also exploring saRNA approaches for new targets (via R&D collaborations) | https://www.biologicale.com/ |
| 26 | Sinergium Biotech Argentina | Vaccine development & manufacturing (influenza, COVID-19, etc.), including pandemic preparedness | Partner in WHO mRNA hub; developed H5N1 avian influenza mRNA vaccine candidates (leading a project to validate in preclinical models); previously licensed a COVID-19 mRNA candidate (with Providence Therapeutics) | Modified mRNA–LNP vaccines (via WHO hub technology); focusing on pandemic flu (H5N1) mRNA platforms | https://www.sinergiumbiotech.com/en/ |
| 32 | WHO mRNA Technology Transfer Hub (Afrigen Biologics/SAMRC/Biovac) South Africa (Global) | Vaccine R&D capacity building in LMICs | WHO-designated hub for disseminating mRNA vaccine technology to low- and middle-income countries. The South Africa hub (Afrigen, with SAMRC and Biovac) produced a pilot mRNA COVID-19 vaccine based on Moderna’s design and in 2024 successfully transferred the technology to partner sites on several continents. The hub has expanded to 15+ manufacturing partners worldwide and spurred innovations like new lipid nanoparticle formulations. By training scientists and sharing know-how, this program is establishing sustainable mRNA vaccine manufacturing and development capacity in regions that previously had none. | mRNA vaccine platform (LNP-based, distributed manufacturing and training) | https://www.who.int/ |
| 1 | Academy of Military Medical Sciences (PLA Academy of Military Sciences) China | Vaccine R&D for emerging infections | Developed ARCoV, China’s first mRNA COVID-19 vaccine, in collaboration with Suzhou Abogen and Walvax. In preclinical studies, ARCoV induced high neutralizing antibodies and protective T-cell responses. Notably, the team achieved a formulation stable at room temperature for one week, easing distribution challenges. ARCoV entered Phase 3 trials and was authorized in 2022–2023, marking a major advance for China’s domestic mRNA vaccine capacity. | mRNA vaccines (LNP-based, with improved thermal stability) | N/A (military research institute) |